Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB062079 in advanced hepatocellular carcinoma and other malignancies
NCT03144661Phase 1Terminated
- Sponsor
- Incyte
- Start
- May 2017
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of INCB062079 in hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), esophageal cancer and 3 more (8 arms), sponsored by Incyte. Primary endpoint: Adverse Events. Started May 2017; status: terminated.
02
Drugs
INCB062079
03
Conditions
hepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)esophageal cancernasopharyngeal carcinoma (NPC)ovarian cancer
Beyond the preview
Go deeper on NCT03144661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03144661.